BRCA1 and neoplasm: A similar trend was previously reported in mouse embryonic fibroblasts (Bunting et al, 2012), suggesting that BRCA1/53BP1‐deficient, olaparib‐resistant tumours may be also more responsive to cisplatin in the clinic.